Telaglenastat (CB-839)

製品コードS7655 バッチS765510

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

 C26H24F3N7O3S
分子量 571.57 CAS No. 1439399-58-2
Solubility (25°C)* 体外 DMSO (warmed with 50ºC water bath) 100 mg/mL (174.95 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 CB-839 (Telaglenastat) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
in vitro

Telaglenastat (CB-839) exhibits time-dependent and slowly reversible kinetics. Its IC50 values for glutaminase inhibition following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. This compound has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.[1]
in vivo

In the mouse TNBC model, single agent Telaglenastat (CB-839) (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, this compound alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, while its combination with NSC 125973 (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors, resulting in a TGI relative to vehicle control of 100%.[1]

プロトコル(参考用のみ)

キナーゼアッセイ Inhibition of CB-839 on rHu-GAC
The enzymatic activity is measured in assay buffer containing 50 mM Tris-Acetate pH 8.6, 150 mM K2HPO4 , 0.25 mM EDTA, 0.1 mg/mL bovine serum albumin, 1 mM DTT, 2 mM NADP+ and 0.01% Triton X-100. To measure inhibition by Telaglenastat (CB-839), the inhibitor (prepared in DMSO) is first pre-mixed with glutamine and glutamate dehydrogenase (GDH) and reactions are initiated by the addition of rHu-GAC. Final reactions contains 2 nM rHu-GAC, 10 mM glutamine, 6 units/mL GDH and 2% DMSO. Generation of NADPH is monitored by fluorescence (Ex340/Em460 nm) every minute for 15 minutes on a SpectraMax M5e plate reader. Relative fluorescence units (RFU) are converted to units of NADPH concentration (µM) using a standard curve of NADPH. Each assay plate incorporates control reactions that monitores the conversion of glutamate (1 to 75 µM) plus NADP+ to α-ketoglutarate plus NADPH by GDH. Under these assay conditions, up to 75 µM glutamate is stoichiometrically converts to α-ketoglutarate/NADPH by GDH. Initial reaction velocities are calculated by fitting the first 5 minutes of each progress curve to a straight line. Inhibition curves are fitted to a four-parameter dose response equation of the form: % activity = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)).
細胞アッセイ 細胞株 HCC1806, MDA-MB-231, and T47D cells
濃度 0.1-1000 nM
反応時間 72 h
実験の流れ

For viability assays, all cell lines are treated with Telaglenastat (CB-839) at the indicated concentrations for 72 hours and analyzed for antiproliferative effects using Cell Titer Glo.
動物実験 動物モデル Female Scid/Bg mice bearing TNBC or JIMT-1 xenograft
投薬量 200 mg/kg
投与方法 p.o.

参考

  • https://pubmed.ncbi.nlm.nih.gov/24523301/

カスタマーフィードバック

Data from [Data independently produced by , , Haematologica, 2018, doi:10.3324/haematol.2018.204701]

Data from [Data independently produced by , , Br J Cancer, 2018, 118(8):1074-1083]

Data from [Data independently produced by , , Biochem Pharmacol, 2018, 156:204-214]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming [ Signal Transduct Target Ther, 2025, 10(1):271] PubMed: 40854873
Chaperone-mediated autophagy directs a dual mechanism to balance premature senescence and senolysis to prevent intervertebral disc degeneration [ Bone Res, 2025, 13(1):62] PubMed: 40506462
GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome [ Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694] PubMed: 39905842
The metabolic shift of glutaminase 2 to glutaminase 1 promotes LGR5 + progenitor cell proliferation in liver cirrhosis [ Cell Mol Life Sci, 2025, 82(1):251] PubMed: 40550888
Endogenous protein S100A14 stabilizes glutaminase to render hepatocellular carcinoma resistant to sorafenib [ J Transl Med, 2025, 23(1):435] PubMed: 40217256
Autophagic flux-lipid droplet biogenesis cascade sustains mitochondrial fitness in colorectal cancer cells adapted to acidosis [ Cell Death Discov, 2025, 11(1):21] PubMed: 39856069
Imaging the uptake and metabolism of glutamine in prostate tumor models using CEST MRI [ Npj Imaging, 2025, 3(1):34] PubMed: 40750673
Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumors [ bioRxiv, 2025, 2025.07.15.664730] PubMed: 40791359
PP2A activation drives aberrant macropinocytosis and cell death in pancreatic ductal adenocarcinoma [ bioRxiv, 2025, 2025.07.14.664742] PubMed: 40791444
Macrophages excite muscle spindles with glutamate to bolster locomotion [ Nature, 2024, 10.1038/s41586-024-08272-5] PubMed: 39633045

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。